These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 12752845)
1. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women. Lee CC; Kasa-Vubu JZ; Supiano MA J Am Geriatr Soc; 2003 May; 51(5):683-8. PubMed ID: 12752845 [TBL] [Abstract][Full Text] [Related]
2. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study. Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D Menopause; 2004; 11(2):167-75. PubMed ID: 15021446 [TBL] [Abstract][Full Text] [Related]
3. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Neele SJ; Evertz R; De Valk-De Roo G; Roos JC; Netelenbos JC Bone; 2002 Apr; 30(4):599-603. PubMed ID: 11934652 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238 [TBL] [Abstract][Full Text] [Related]
6. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Goldstein SR; Johnson S; Watts NB; Ciaccia AV; Elmerick D; Muram D Menopause; 2005 Mar; 12(2):160-4. PubMed ID: 15772563 [TBL] [Abstract][Full Text] [Related]
7. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene. Tommaselli GA; Di Carlo C; Di Spiezio Sardo A; Bifulco G; Cirillo D; Guida M; Capasso R; Nappi C Menopause; 2006; 13(4):660-8. PubMed ID: 16837888 [TBL] [Abstract][Full Text] [Related]
8. Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial. Usall J; Huerta-Ramos E; Labad J; Cobo J; Núñez C; Creus M; Parés GG; Cuadras D; Franco J; Miquel E; Reyes JC; Roca M; Schizophr Bull; 2016 Mar; 42(2):309-17. PubMed ID: 26591005 [TBL] [Abstract][Full Text] [Related]
9. Estrogen or raloxifene during postmenopausal weight loss: adiposity and cardiometabolic outcomes. Van Pelt RE; Gozansky WS; Wolfe P; Kittelson JM; Jankowski CM; Schwartz RS; Kohrt WM Obesity (Silver Spring); 2014 Apr; 22(4):1024-31. PubMed ID: 24311443 [TBL] [Abstract][Full Text] [Related]
10. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. de Valk-de Roo GW; Stehouwer CD; Meijer P; Mijatovic V; Kluft C; Kenemans P; Cohen F; Watts S; Netelenbos C Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2993-3000. PubMed ID: 10591680 [TBL] [Abstract][Full Text] [Related]
11. Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis. Modugno F; Ness RB; Ewing S; Cauley JA Obstet Gynecol; 2003 Feb; 101(2):353-61. PubMed ID: 12576261 [TBL] [Abstract][Full Text] [Related]
12. Raloxifene modifies the insulin sensitivity and lipid profile of postmenopausal insulin resistant women. Grover-Páez F; Zavalza-Gómez AB; Anaya-Prado R Gynecol Endocrinol; 2013 Jul; 29(7):674-7. PubMed ID: 23638622 [TBL] [Abstract][Full Text] [Related]
13. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Cheng WC; Yen ML; Hsu SH; Chen KH; Tsai KS Endocrine; 2004; 23(2-3):215-8. PubMed ID: 15146102 [TBL] [Abstract][Full Text] [Related]
14. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial. Kianimehr G; Fatehi F; Hashempoor S; Khodaei-Ardakani MR; Rezaei F; Nazari A; Kashani L; Akhondzadeh S Daru; 2014 Jul; 22(1):55. PubMed ID: 25012765 [TBL] [Abstract][Full Text] [Related]
15. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. Cagnacci A; Paoletti AM; Zanni A; Arangino S; Ibba G; Orrù M; Melis GB; Volpe A J Clin Endocrinol Metab; 2002 Sep; 87(9):4117-21. PubMed ID: 12213858 [TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Mijatovic V; Netelenbos C; van der Mooren MJ; de Valk-de Roo GW; Jakobs C; Kenemans P Fertil Steril; 1998 Dec; 70(6):1085-9. PubMed ID: 9848300 [TBL] [Abstract][Full Text] [Related]
17. The effect of raloxifene on glyco-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study. Cucinelli F; Soranna L; Romualdi D; Muzj G; Mancuso S; Lanzone A J Clin Endocrinol Metab; 2002 Sep; 87(9):4186-92. PubMed ID: 12213869 [TBL] [Abstract][Full Text] [Related]
19. Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. Duschek EJ; Neele SJ; Thomassen MC; Rosing J; Netelenbos C Blood Coagul Fibrinolysis; 2004 Oct; 15(8):649-55. PubMed ID: 15613919 [TBL] [Abstract][Full Text] [Related]
20. Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women. Lasco A; Gaudio A; Morabito N; Previti M; Mileto A; Frisina N; Cucinotta D Diabetologia; 2004 Mar; 47(3):571-574. PubMed ID: 14762655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]